Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6397 (Published 13 October 2011) Cite this as: BMJ 2011;343:d6397- Robert J C Steele, clinical director 1,
- David H Brewster, director2
- 1Scottish Bowel Screening Programme
- 2Scottish Cancer Registry, Edinburgh, UK
- Correspondence to: R J C Steele, Surgery and Molecular Oncology, Ninewells Hospital and Medical School Dundee, Dundee DD1 9SY, UK r.j.c.steele{at}dundee.ac.uk
All medical interventions have the potential to cause harm. This is particularly important in the case of cancer screening because the intervention is offered to people who are, or at least believe themselves to be, in good health, and the tolerance limit of harm must accordingly be low.
Screening may cause harm in several ways.1 If the screening test is not highly sensitive, false negative results may induce reassurance and create a “certificate of health effect.” In other words, people who have received a false negative test result may ignore symptoms or continue to engage in risky behaviour. Then the test itself can cause harm—for example, colonoscopy as a consequence of colorectal screening may lead to colonic perforation or other complications, and this must be monitored. Given that most people who are screened will not have disease, unnecessary psychological morbidity may also be created. Finally, screening inevitably leads to a degree of overdiagnosis —that is, people will be found to have disease that …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.